|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||1.0140 - 1.1000|
|52 Week Range||1.0140 - 4.6600|
|Beta (3Y Monthly)||0.33|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.50|
The most recent earnings announcement EOS imaging SA's (EPA:EOSI) released in December 2018 confirmed that losses...
EOS imaging (EOSI.PA) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announced its fourth EOS system installation at the Hospital for Special Surgery (HSS), which has been ranked #1 in the U.S. for Orthopedics by U.S. News & World Report for the past nine consecutive years. HSS is the world’s largest academic medical center dedicated to musculoskeletal health, performing more than 33,000 surgical procedures a year. “Patients come to HSS from more than 80 countries and all 50 of the United States because we deliver the most advanced diagnosis, treatment and care for even the most complex cases, so it’s important that we continue to lead also in low dose imaging” said Roger Widmann, MD, Spine Surgeon and Chief of Pediatric Orthopedic Surgery at HSS.
The new hospital, a joint venture of the Al Tayer Group, Dubai Investments and the UK group Ashmore, is located in the district of Dubai Hills and has a capacity of 100 beds. The King’s College Hospital Dubai enjoys a direct link to King's College Hospital in London, a prestigious facility for the treatment of complex diseases and one of the largest medical education centers in the United Kingdom.
Symposium to be led by Dr. Peter K. Sculco and Pr. Jean-Yves Lazennec on Tuesday, March 12
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While small-cap stocks, such as EOS imagingRead More...
EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), the pioneer of 2D/3D imaging and data solutions for orthopedics, previously announced in a press release dated December 11th, 2018, the success of the settlement-delivery of the share capital increase for an amount of €15,061,856.13 entirely subscribed by Fosun Pharmaceutical AG, an indirect subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK) ("Fosun") through an issuance of EOS imaging 3,446,649 new shares ("New Shares") at a subscription price of €4.37 per share (the "Share Capital Increase"). Pursuant to the subscription agreement related to the Share Capital Increase entered into by EOS imaging and Fosun on July 17th, 2018 (the "Subscription Agreement"), and subject to certain exemptions detailed in the securities note dated December 7th, 2018, which received the visa number 18-551 from the French financial markets authority, EOS imaging has agreed to offer Fosun the possibility, during the period beginning from the date of completion of the Share Capital Increase and continuing until the expiry of a five years period, so long as Fosun owns at least 25% of the New Shares, to subscribe to share capital increases which would be implemented without preferential subscription rights.
A look at the shareholders of EOS imaging SA (EPA:EOSI) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...
EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME) (EOSI.PA) ("EOS imaging" or the "Company"), the pioneer of 2D/3D imaging and data solutions for orthopedics, previously announced in a press release dated July 17th, 2018 having entered into a binding agreement (the "Subscription Agreement") with Fosun Pharmaceutical AG, an indirect subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK) ("Fosun") related to an equity investment to be made by Fosun Pharmaceutical AG through an issuance of EOS imaging new shares (the "Share Capital Increase").
Symposium to showcase Total Hip Arthroplasty results with EOS analysis
EOS imaging (EOSI.PA) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), the pioneer of orthopedic medical imaging 2D / 3D, announces the change of its leadership effective January 1, 2019. The Board of Directors, in agreement with Marie Meynadier, Chief Executive Officer of EOS imaging, has decided to change the leadership of the company to strengthen the company’s presence in the United States, its largest market, and expand its shareholder base.
Booth presentation on THA planning from EOS images by Dr. Mayman, Orthopedic Surgeon and Clinical Co-Director, Computer Assisted Surgery Center at the Hospital for Special Surgery
Anyone researching EOS imaging SA (EPA:EOSI) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Read More...
PARIS-- -- stereoVIEW, a software dedicated to clinical collaboration and patient engagement, and the new EOS online learning platform will be demonstrated at EOS Booth #113 Results from a study on 3D spine reconstruction using deep learning will be presented for the first time Regulatory News: EOS imaging , a pioneer in 2D / 3D orthopedic medical imaging, will present its 2D / 3D collaborative data ...
Internationally recognized leaders in total hip arthroplasty to present the value of EOS along the hip care pathway through 7 podium presentations and 3 posters
spineEOS, part of the EOSapps suite of online 3D surgical planning solutions, will be presented by a renowned surgeon in EOS Booth #2314
EOS imaging SA’s (EPA:EOSI): EOS imaging SA designs, develops, markets, and sells medical imaging devices for osteo-articular conditions and orthopedics, and related applications. On 31 December 2017, the €99.3m market-capRead More...